Full-Time

Quality Compliance Associate 1/2

Capricor Therapeutics

Capricor Therapeutics

201-500 employees

Biotech developing cell- and exosome therapeutics

Compensation Overview

$70k - $82k/yr

San Diego, CA, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
Quality Assurance (QA)
Requirements
  • Bachelor's degree in a scientific or technical field (e.g., Chemistry, Biology, Engineering) or equivalent experience.
  • 1-2 years of auditing experience within biopharma, biotech, medical devices, or related regulated industry.
  • Working knowledge of FDA 21 CFR Parts 210/211, ICH Q-series, EU GMP, and GDP principles.
  • Experience performing audits against quality system elements (Deviation, CAPA, Change Control, Training, Document Control).
  • Strong technical writing skills and attention to detail; able to produce clear, evidence-based audit reports.
  • Proficiency with risk-based auditing, root cause analysis, and CAPA effectiveness verification.
  • Excellent communication and stakeholder management skills; comfortable engaging at all levels.
Responsibilities
  • Plan, execute, and report on internal audits of GxP processes (e.g., GMP manufacturing, QC, validation, laboratories, supply chain).
  • Lead or support supplier/vendor audits and monitor ongoing supplier performance.
  • Prepare detailed audit agendas, checklists, and sampling strategies aligned with risk and compliance priorities.
  • Document findings clearly; issue audit reports with classifications, evidence, and actionable recommendations.
  • Track and verify effectiveness of CAPAs (Corrective and Preventive Actions) and drive timely closure.
  • Support inspection readiness activities and host/liaise during regulatory inspections (e.g., FDA, EMA, MHRA).
  • Perform gap assessments against current regulations and industry standards; propose reasonable improvements.
  • Collaborate with QA/QC, Manufacturing, Regulatory, Supply Chain, and IT to strengthen quality systems.
  • Maintain audit schedules, metrics, and dashboards; communicate status to stakeholders and management.
  • Contribute to policy/SOP development, training, and continuous improvement initiatives.
Desired Qualifications
  • Certified Quality Auditor (CQA) – ASQ, or equivalent certification.
  • Experience auditing CMOs/CDMOs and complex supply chains.
  • Background with data integrity, CSV, Annex 11, and Part 11 assessments.
  • Exposure to biologics, cell & gene therapy, aseptic processing, or sterile manufacturing.
  • Knowledge of ISO 9001/13485, 21 CFR 210/211, and pharmacovigilance quality systems (as applicable).
Capricor Therapeutics

Capricor Therapeutics

View

Capricor Therapeutics develops cell- and exosome-based therapies to treat serious diseases. Its products use cells or tiny vesicles released by cells to repair heart tissue, Duchenne muscular dystrophy, and COVID-19–related complications, and are advanced through research and clinical trials before potential commercialization. It differentiates itself by focusing on cell- and exosome-based approaches rather than small molecules, pursuing a portfolio aimed at high-need conditions. The company’s goal is to improve patient outcomes by validating these therapies and bringing them to hospitals and healthcare providers, supported by partnerships and grants.

Company Size

201-500

Company Stage

IPO

Headquarters

Beverly Hills, California

Founded

2005

Your Connections

People at Capricor Therapeutics who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • HOPE-3 met primary PUL 2.0 and key cardiac endpoints, strengthening approval odds.[3][5]
  • Capricor targets an August 22, 2026 PDUFA decision for deramiocel.[3][5]
  • The company is expanding manufacturing capacity and commercial infrastructure before launch.[3]

What critics are saying

  • FDA review remains binary after the earlier CRL and resubmission process.[5]
  • The NS Pharma dispute threatens U.S. commercialization even if approval arrives.[3]
  • Capricor remains highly dependent on deramiocel, with preclinical exosome programs unproven.[1][3]

What makes Capricor Therapeutics unique

  • Deramiocel is an allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy.[3]
  • Capricor combines cell therapy and proprietary exosome platforms in rare diseases.[1][3]
  • Its U.S. commercialization agreement with Nippon Shinyaku adds an external launch channel.[3]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Staff Training (not in predefined)

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

10%

2 year growth

3%
Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces $23 Million Registered Direct Offering

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market

LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results

HOPE-Duchenne and ALLSTAR Clinical Trials on Track to Complete Enrollment in the Third Quarter Company to Host Conference Call and Webcast at 4:30…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces $7 Million Private Placement of Common Stock

Institutional Investors Include: Broadfin Capital, LLC and Sabby Capital, LLC LOS ANGELES, Feb. 4, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics,…...